Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval

April 4, 2016 • by Marc Airhart

The anthrax antitoxin obiltoxaximab received approval March 21 from the U.S. Food and Drug Administration (FDA).

White bacterial coloines on a plate of red culture medium

Colonies of the bacterium Bacillus anthracis, which causes anthrax, at 10x magnification. Photo credit: Todd Parker/CDC.


Share